# NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries

> **NCT04081103** · PHASE2 · TERMINATED · sponsor: **Glaukos Corporation** · enrollment: 35 (actual)

## Conditions studied

- Corneal Persistent Epithelial Defect

## Interventions

- **DRUG:** Nexagon® (lufepirsen) High Dose Concentration
- **DRUG:** Nexagon® (lufepirsen) Low Dose Concentration
- **DRUG:** Vehicle
- **DRUG:** Open-label Nexagon® (lufepirsen)

## Key facts

- **NCT ID:** NCT04081103
- **Lead sponsor:** Glaukos Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-06-30
- **Primary completion:** 2022-02-07
- **Final completion:** 2022-02-07
- **Target enrollment:** 35 (ACTUAL)
- **Why stopped:** The study was stopped early (n=35) enabling the data to guide design of the subsequent clinical study.
- **Last updated:** 2025-07-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04081103

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04081103, "NEXAGON for the Treatment of Corneal Persistent Epithelial Defects Following Severe Ocular Injuries". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04081103. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*